Citations

Clear

65 citation(s) found for "Fox, Michael".

Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay
Chahine, Lana M. , Beach, Thomas G. , Hepker, Monica, Kanthasamy, Anumantha G. , Appel, Scott, Pritzkow, Sandra , Pinho, Michelle, Mosovsky, Sherri, Coffey, Christopher S. , Oliveira, Luís M. A. , Eberling, Jamie L., Mollenhauer, Brit , Study, For the Systemic Synuclein Sampling, Amara, Amy W. , Kanthasamy, Anumantha , Visanji, Naomi P , Adler, Charles H. , Serrano, Geidy E. , Brumm, Michael C. , Study, For the Systemic Synuclein Sampling

Mayo Clinic

Annals of Clinical and Translational Neurology | March 28, 2023 | Volume: 10 | Issue: 5 | Pages: 696-705

10.1002/acn3.51753 | PMID 36972727 Get It

AbstractObjectivesDetection of α‐synuclein aggregates by seed amplification is a promising Parkinson disease biomarker assay. Understanding intraindividual relationships of α‐synuclein measures could inform optimal biomarker development. The objectives were to test accuracy of α‐synuclein seed amplification assay in central (cerebrospinal fluid) and peripheral (submandibular gland) sources, compare to total α‐synuclein measures, and investigate within‐subject relationships.MethodsThe Systemic Synuclein Sampling Study aimed to characterize α‐synuclein in multiple tissues and biofluids within Parkinson disease subjects (n = 59) and compared to healthy controls (n = 21). Motor and non‐motor measures and dopamine transporter scans were obtained. Four measures of α‐synuclein were compared: seed amplification assay in cerebrospinal fluid and formalin‐fixed paraffin‐embedded submandibular gland, total α‐synuclein quantified in biofluids using enzyme‐linked immunoassay, and aggregated α‐synuclein in submandibular gland detected by immunohistochemistry. Accuracy of seed amplification assay for Parkinson disease diagnosis was examined and within‐subject α‐synuclein measures were compared.ResultsSensitivity and specificity of α‐synuclein seed amplification assay for Parkinson disease diagnosis was 92.6% and 90.5% in cerebrospinal fluid, and 73.2% and 78.6% in submandibular gland, respectively. 25/38 (65.8%) Parkinson disease participants were positive for both cerebrospinal fluid and submandibular gland seed amplification assay. Comparing accuracy for Parkinson disease diagnosis of different α‐synuclein measures, cerebrospinal fluid seed amplification assay was the highest (Youden Index = 83.1%). 98.3% of all Parkinson disease cases had ≥1 measure of α‐synuclein positive.Interpretationα‐synuclein seed amplification assay (cerebrospinal fluid>submandibular gland) had higher sensitivity and specificity compared to total α‐synuclein measures, and within‐subject relationships of central and peripheral α‐synuclein measures emerged.
Charting Trends in Medicare Reimbursement for Lower Extremity Imaging
Lebaron, Zachary , Brown, Parker J. , Minzer, Ian D., Brinkman, Joseph C. , Hinckley, Nathaniel B. , Fox, Michael G. , Hinckley, Nathaniel, Richman, Evan H. , Patel, Karan A.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | March 21, 2023 | Volume: 11 | Issue: 3 | Pages: No page available

10.1177/23259671221147264 | PMID 36970321 Get It

Background: Medicare reimbursement is rapidly declining in many specialties. An in-depth analysis of Medicare reimbursement for routinely performed diagnostic imaging procedures in the United States is warranted. Purpose/Hypothesis: The purpose of this study was to evaluate Medicare reimbursement trends for the 20 most common lower extremity imaging procedures performed between 2005 and 2020, including radiographs, computed tomography (CT), and magnetic resonance imaging (MRI). We hypothesized that Medicare reimbursement for imaging procedures would decline substantially over the studied period. Study Design: Cohort study. Methods: The Physician Fee Schedule Look-up Tool from the Centers for Medicare and Medicaid Services was analyzed for reimbursement rates and relative value units associated with the top 20 most utilized Current Procedural Terminology (CPT) codes in lower extremity imaging from 2005 to 2020. Reimbursement rates were adjusted for inflation and listed in 2020 US dollars using the US Consumer Price Index. To compare year-to-year changes, the percentage change per year and compound annual growth rate were calculated. A 2-tailed t test was used to compare the unadjusted and adjusted percentage change over the 15-year period. Results: After adjusting for inflation, mean reimbursement for all procedures decreased by 32.41% ( P = .013). The mean adjusted percentage change per year was –2.82%, and the mean compound annual growth rate was –1.03%. Compensation for the professional and technical components for all CPT codes decreased by 33.02% and 85.78%, respectively. Mean compensation for the professional component decreased by 36.46% for radiography, 37.02% for CT, and 24.73% for MRI. Mean compensation for the technical component decreased by 7.76% for radiography, 127.66% for CT, and 207.88% for MRI. Mean total relative value units decreased by 38.7%. The commonly billed imaging procedure CPT 73720 (MRI lower extremity, other than joint, with and without contrast) had the greatest adjusted decrease of 69.89%. Conclusion: Medicare reimbursement for the most billed lower extremity imaging studies decreased by 32.41% between 2005 and 2020. The greatest decreases were noted in the technical component. Of the modalities, MRI had the largest decrease, followed by CT and then radiography.
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
Vollstedt, Eva‐Juliane , Schaake, Susen , Lohmann, Katja , Lesage, Suzanne , Tesson, Christelle , Wurster, Isabel , Hentati, F., Marder, Karen, Waters, Cheryl , Fahn, Stanley, Brüggemann, Norbert , Tolosa, Eduardo , Garrido, Alícia , Annesi, Grazia , Bozi, Maria , Ferreira, Joaquim J. , Guedes, Leonor Correia , Petrucci, Simona , Clark, Lorraine N. , Abramycheva, Natalya, Menéndez‐González, Manuel , Maestre, S. Jesús, Gómez‐Garre, Pilar , Mir, Pablo , Ran, Caroline , Kuo, Ming‐Che , Ross, Owen A. , Williams‐Gray, Caroline H. , Camacho, Marta , Cornejo‐Olivas, Mario , Torres-Ramírez, Luis , Wu, Yih‐Ru , Morgadinho, Ana , Berg, Daniela , Kuhlenbäumer, Gregor , Kühn, Andrea A. , Borngräber, Friederike , Michele, Giuseppe De , Rosa, Anna De , Zimprich, Alexander , Puschmann, Andreas , Mellick, George D. , Chase, Bruce A. , Markopoulou, Katerina , Satake, Wataru , Rossi, Malco , Lynch, Timothy , Olszewska, Diana A. , Lim, Shen‐Yang , Ahmad‐Annuar, Azlina , Tan, Ai Huey , Hanağası, Haşmet , Koziorowski, Dariusz , Ertan, Sibel , Genç, Gençer , Saunders‐Pullman, Rachel , Warrenburg, Bart van de, Bressman, Susan , Toft, Mathias , Appel‐Cresswell, Silke , Boon, Agnita J.W. , Krüger, Rejko , Sammler, Esther , Tumas, Vítor , Zhang, Baorong , Garraux, Gaëtan , Kim, Yun Joong , Winkelmann, Juliane , Sue, Carolyn M. , Tan, Eng‐King , Kostić, Vladimir , Arkadir, David , Martikainen, Mika H. , Brighina, Laura , Suchowersky, Oksana , Rieß, Olaf , Das, Parimal, Mollenhauer, Brit , Gatto, Emilia , Petersen, Maria Skaalum , Aasly, Jan , Aasly, Anna, Farrer, Matthew J. , Brockmann, Kathrin , Klein, Christine , Group, the MJFF Global Genetic Parkinson's Disease Study, Bardien, Soraya , Barrett, Matthew J. , Januário, Cristina , Sousa, Mário , Soto‐Beasley, Alexandra I. , May, Patrick , Mirelman, Anat , Brüggemann, Norbert , Borsche, Max , Tolosa, Eduardo , Ferreira, Joaquim J , Alvarez, Victoria , Mir, Pablo , Kuo, Ming-Che , Ross, Owen A , Nishioka, Kenya , Williams-Gray, Caroline H , Camacho, Marta , Cornejo-Olivas, Mario , Wu, Yih-Ru , Termsarasab, Pichet , Borngräber, Friederike , Zimprich, Alexander , Gambardella, Stefano , Chase, Bruce , Olszewska, Diana A , Tan, Ai Huey , Barkhuizen, Melinda , Appel-Cresswell, Silke , Skorvanek, Matej , Sammler, Esther M , Zhang, Baorong , Chung, Sun Ju , Puschmann, Andreas , Januário, Cristina , Klein, Christine , Bardien, Soraya , Toft, Mathias , Koziorowski, Dariusz , May, Patrick , Beasley, Alexandra I , Barrett, Matthew J , Sue, Carolyn M , Kühn, Andrea A , Padmanabhan, Shalini , Brice, Alexis , Vidailhet, Marie , Giladi, Nir , Kasten, Meike , Borsche, Max , Foroud, Tatiana , Gagliardi, Monica , Stefanis, Leonidas , Avenali, Micol , Fedotova, E. Yu. , Álvarez, Victoria , Belin, Andrea Carmine , Lin, Chin‐Hsien , Crosiers, David , Wszołek, Zbigniew K. , Jankovic, Joseph J. , Funayama, Manabu , Clarimón, Jordi , Lee‐Chen, Guey‐Jen , Pulkes, Teeratorn , Dorszewska, Jolanta , Carr, Jonathan , Ferese, Rosangela , Toda, Tatsushi , Merello, Marcelo , Al-Mubarak, Bashayer R , Aguiar, Patrícia de Carvalho , Pimentel, Márcia Mattos Gonçalves , Warrenburg, Bart P.C. van de , Lang, Anthony E. , Damásio, Joana , Klivènyi, Péter , Borges, Vanderci , Hertz, Jens Michael , Spitz, Mariana , Hattori, Nobutaka , Wu, Ruey‐Meei , Illarioshkin, Sergey Nikolaevich , Valente, Enza Maria , Alcalay, Roy N. , Thaler, Avner , Corvol, Jean‐Christophe , Group, the MJFF Global Genetic Parkinson's Disease Study

Mayo Clinic

Movement Disorders | January 24, 2023 | Volume: 38 | Issue: 2 | Pages: 286-303

10.1002/mds.29288 | PMID 36692014 Get It

AbstractBackgroundAs gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial‐ready cohorts is limited.ObjectiveThe objectives are to (1) establish an international cohort of affected and unaffected individuals with PD‐linked variants; (2) provide harmonized and quality‐controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD.MethodsWe conducted a worldwide, systematic online survey to collect individual‐level data on individuals with PD‐linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ‐1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed.ResultsWe collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ‐1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published.ConclusionsWithin the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD‐linked variants; (2) provide harmonized and quality‐controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene‐targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Postoperative Ankle Imaging, 2022
Sill, Andrew , Haug, Logan P. , Kile, Todd A. , Fox, Michael G. , Shrestha, Roman , Sill, Andrew P., Fox, Michael G , Shrestha, Roman, Patel, Karan A.

Mayo Clinic

Seminars in Musculoskeletal Radiology | June 2, 2022 | Volume: 26 | Issue: 03 | Pages: 203-215

10.1055/s-0042-1750841 | PMID 35654090 Get It

Abstract Postoperative ankle imaging requires knowledge of the underlying surgical techniques, the usefulness of various imaging modalities, as well as an appreciation for the desired clinical outcomes. Surgical procedures discussed in this article are tibiotalar fracture fixation, tibiotalar, subtalar, and tibiotalocalcaneal arthrodesis, total ankle arthroplasty, talar osteochondral lesion repair and grafting, lateral ligamentous repair and reconstruction, and peroneal and Achilles tendon repair and reconstruction. Imaging can play a vital role in determining if the expected outcome has been achieved and identifying complications, with particular emphasis placed on the use of radiographs, computed tomography (including weight-bearing), magnetic resonance imaging, and ultrasonography.
Abstract WP148: The BRIDGE Project ( BRIDG ing the gap in strok E management):Trans-Atlantic Differences in Management of Carotid Stenosis
Balucani, Clotilde , Arnedo, Vanessa , Mas, Jean‐Louis , Brown, Martin M. , Gonzales, Nicole R. , Savitz, Sean I. , Hacke, Werner , Brott, Thomas G. , Leys, Didier , Grotta, James C. , Levine, Steven R.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 44 | Issue: suppl_1 | Pages: No page available

10.1161/str.44.suppl_1.awp148 Get It

Background: Optimum management of carotid stenosis, both symptomatic (sx) and asymptomatic (asx), remains controversial despite clinical trials evaluating Carotid Endarterectomy (CEA) and Carotid Stenting (CAS). Objective: We compared attitudes in management of carotid stenosis between experts in Europe (EU), and North America (NA). Methods: From April 2011 to July 2012, a 3-round, email-Delphi survey was sent to members of the European Stroke Organisation (n=390) and to a list of NA stroke neurologists developed at the University of Texas at Houston Stroke Program (n=289). Those completing the survey were shown all responses broken down by EU/NA after each of the first 2 survey rounds. Continent specific consensus was defined a priori to be > 80% agreement. Results: 100 (15%, of which 73% EU) participated in all 3-Delphi rounds, 19% of all EU vs 9% NA (χ2=11.62, p=0.0007): 76% male; 69% treating between 1-8 new cases of carotid stenosis per month. In the final round, EU reached consensus in 7/11 statements (3 reached in phase-I), while NA did in 4/11 (1 reached in phase-I).Ninety-percent of EU vs 70% of NA (χ2=8.09, p=0.017) disagreed that CAS and CEA are equivalent treatments for sx carotid stenosis, and stated that CEA is superior. There remains a significant difference between EU and NA when considering ipsilateral stroke and death < 30 days as primary outcome (χ2=12.18, p=0.007). Sixty-nine-percent of NA agreed that there is a stronger indication for CAS over CEA in patients < 65 years for sx carotid stenosis whereas 55% of EU (χ2=11.39, p=0.023) disagreed with the statement. When asked how likely they would recommend CEA for an asx carotid stenosis, 81% of EU and 80% of NA said ‘sometimes’. When asked how likely they would recommend CAS for an asx carotid stenosis, 62% of NA said ‘sometimes’ vs 60% of EU said ‘never’(χ2=3.54, p=0.06). Conclusion: There are several clear differences in attitudes regarding the management of carotid stenosis between EU and NA: EU has a stronger attitude towards superiority of CEA while in NA there is more equipoise between the two treatments. Areas of lack of consensus may provide direction for future clinical trials.
Sex-specific lesion pattern of functional outcomes after stroke
Bretzner, Martin , Hong, Sung‐Min , Schirmer, Markus D. , Cohen, Alexander L. , Regenhardt, Robert W. , Donahue, Kathleen, Nardin, Marco, Etherton, Mark R. , Hancock, Brandon L., Mocking, Steven J. T. , McIntosh, Elissa C. , Benavente, Oscar, Donatti, Amanda , Heitsch, Laura , Jiménez-Conde, Jordi , Kittner, Steven J. , Levi, Christopher , Rolfs, Arndt , Schmidt, Reinhold , Sharma, Pankaj , Słowik, Agnieszka , Söderholm, Martin , Sousa, Alessandro , Stanne, Tara M. , Strbian, Daniel , Thijs, Vincent , Wassélius, Johan , Woo, Daniel , Zand, Ramin , McArdle, Patrick F. , Worrall, Bradford B. , Maguire, Jane , Fox, Michael , Bzdok, Danilo , Wu, Ona , Rost, Natalia S. , Bretzner, Martin , Cohen, Alexander , Etherton, Mark R , Jood, Katarina , Lemmens, Robin , Strbian, Daniel , Regenhardt, Robert W , Wu, Ona , Zand, Ramin , Bonkhoff, Anna K. , Dalca, Adrian Vasile , Giese, Anne‐Katrin , Attia, John , Bevan, Steve , Cole, John W. , Griessenauer, Christoph J. , Holmegaard, Lukas , Lemmens, Robin , McDonough, Caitrin W. , Meschia, James F. , Phuah, Chia‐Ling , Ropele, Stefan , Rosand, Jonathan M. , Roquer, Jaume , Rundek, Tatjana , Sacco, Ralph L. , Tatlisumak, Turgut , Vagal, Achala , Jern, Christina , Lindgren, Arne G.

Mayo Clinic

Brain Communications | January 31, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcac020 | PMID 35282166 Get It

Abstract Stroke represents a considerable burden of disease for both men and women. However, a growing body of literature suggests clinically relevant sex differences in the underlying causes, presentations and outcomes of acute ischaemic stroke. In a recent study, we reported sex divergences in lesion topographies: specific to women, acute stroke severity was linked to lesions in the left-hemispheric posterior circulation. We here determined whether these sex-specific brain manifestations also affect long-term outcomes. We relied on 822 acute ischaemic patients [age: 64.7 (15.0) years, 39% women] originating from the multi-centre MRI-GENIE study to model unfavourable outcomes (modified Rankin Scale &gt;2) based on acute neuroimaging data in a Bayesian hierarchical framework. Lesions encompassing bilateral subcortical nuclei and left-lateralized regions in proximity to the insula explained outcomes across men and women (area under the curve = 0.81). A pattern of left-hemispheric posterior circulation brain regions, combining left hippocampus, precuneus, fusiform and lingual gyrus, occipital pole and latero-occipital cortex, showed a substantially higher relevance in explaining functional outcomes in women compared to men [mean difference of Bayesian posterior distributions (men – women) = −0.295 (90% highest posterior density interval = −0.556 to −0.068)]. Once validated in prospective studies, our findings may motivate a sex-specific approach to clinical stroke management and hold the promise of enhancing outcomes on a population level.
Calcific Tendinosis Reduces Diagnostic Performance of Magnetic Resonance Imaging in the Detection of Rotator Cuff Tears
Sill, Andrew P., Zaw, Taryar, Flug, Jonathan A., Hartigan, David E., Kransdorf, Mark J., Brinkman, Joseph, Fox, Michael G., Sill, Andrew , Zaw, Taryar, Flug, Jonathan A., Hartigan, David E., Kransdorf, Mark J., Brinkman, Joseph, Fox, Michael G.

Mayo Clinic

Journal of Computer Assisted Tomography | November 11, 2021 | Volume: 46 | Issue: 2 | Pages: 219-223

10.1097/rct.0000000000001257 | PMID 35297578 Get It

Objective This study aimed to investigate the effect of calcific tendinosis on the diagnosis of rotator cuff tears (RCTs) on magnetic resonance imaging (MRI) and magnetic resonance arthrography (MRA). Materials and Methods Calcific tendinosis was confirmed radiographically. Two musculoskeletal radiologists then retrospectively and independently reviewed the MRI/MRA examinations, with surgery or arthroscopy performed within 90 days of the MRI. Rotator cuffs were categorized as no tear, partial-thickness tear, and full-thickness tear. Partial-thickness tear/full-thickness tear groups were combined for analysis. Results Forty-eight MRI (mean age, 63.4 years; range, 37–83 years; female-to-male ratio, 29:19) and 7 MRA (mean age, 49.2 years; range, 25–60 years; female-to-male ratio, 4:3) patients were included. Reader 1 and reader 2 sensitivity/specificity values for RCTs on MRI were 95%/50% and 89%/30%, and the values on MRA were 100%/67% and 100%/100%, respectively. Overall agreement was present in 87% (48 of 55; κ = 0.55 [95% confidence interval, 0.26–0.85]). Conclusions Magnetic resonance imaging has decreased specificity in diagnosing RCTs when calcific tendinosis is present. Magnetic resonance arthrography performed better in this population and could be considered.
Risk of bleeding following double balloon enteroscopy in patients on continued antiplatelet and/or anticoagulation therapy
Zaver, Himesh B. , Ghoz, Hassan , Alnahhal, Khaled I. , Malviya, Balkishan, Patel, Krupa , Rodriguez, Andrea C. , Oberoi, Mansi , Koralewski, Andrea, Crawford, Matthew James , Choudhry, Aruj, Mareth, Karl , Werlang, Monia E., Lukens, Frank , Stark, Mark E., Brahmbhatt, Bhaumik , Stancampiano, Fernando, Crawford, Matthew J, Stark, Mark, Stancampiano, Fernando F. , Kröner, Paul T. , Simons-Linares, C. Roberto , Bartel, Michael J.

Mayo Clinic

Endoscopy International Open | August 23, 2021 | Volume: 09 | Issue: 09 | Pages: E1397-E1403

10.1055/a-1499-6988 | PMID 34466365 Get It

Abstract Background and study aims Anticoagulation (AC) and antiplatelet (AP) therapy may increase the risk of gastrointestinal bleeding after double balloon enteroscopy (DBE); however, limited data are currently available regarding the incidence. The aim of this study was to assess the incidence and clinical characteristics of post-DBE bleeding in patients on AC and AP therapy. Patients and methods The medical records of patients who underwent DBE between 2009 and 2013 at Mayo Clinic, Florida, were retrospectively reviewed. Patients were divided into three groups: 1) continued AP therapy; 2) AC therapy; and 3) neither AP nor AC at the time of DBE. Follow-up data were collected at 60 days and 1 year. Results A total of 683 patients were identified; 43 on AC, 183 on AP and 457 not on AP or AC therapy. The most common indication for DBE was obscure gastrointestinal bleeding in the groups on and not on AP (85.3 % vs 70.9 %, P < 0.0001). There was no statistical difference in post-DBE bleeding rates in patients on AP vs not on AP at 60 days (11.5 % vs 7.5 %, P = 0.12) or 1 year (19.9 % vs 15.7 %, P = 0.23). Rates of bleeding in patients on AC were 11.6 % within 60 days and 22.5 % within 1 year. Multivariate analysis reflected American Society of Anesthesiologist > 3 and indication for DBE of GI bleeding were independent risk factors for post-DBE bleeding within 1 year. Conclusions Continued antiplatelet use at the time of DBE was not an independent risk factor for bleeding post-DBE at 60 days or 1 year of follow up.
Differences in management and treatment of traumatic adult pan brachial plexus injuries: a global perspective regarding continental variations
Shin, Alexander Y. , Desai, Ketan, Fox, Michael , Spinner, Robert J. , Shin, Alexander Y , Socolovsky, Mariano , Wang, Shufeng

Mayo Clinic

Journal of Hand Surgery (European Volume) | August 19, 2021 | Volume: 47 | Issue: 1 | Pages: 40-51

10.1177/17531934211039677 | PMID 34407694 Get It

An expert opinion study was designed to query five countries and six brachial plexus surgeons regarding the demographics, mechanisms of injury, evaluation, timing of surgery, reconstructive strategies and controversies in adult traumatic pan brachial plexus injuries. Variations in assessing outcomes, management of neuropathic pain and future considerations were elucidated. Clear differences in regional demographics, mechanisms of injury, patient evaluation and treatment strategies were identified. The role of phrenic nerve and contralateral C7 transfer, acute use of free functioning muscle transfers, root reimplantation and amputation/myoelectric prosthetic fitting were regional/surgeon dependent. Comparison of outcomes across regions requires an understanding of the regional nuances of patient demographics, injury mechanisms, preferred reconstructive strategies and how outcomes are measured. Future studies are required to allow accurate regional comparisons.
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease
Lai, Dongbing , Fontanillas, Pierre , Aasly, Jan , Beecham, Gary W. , Berg, Daniela , Bressman, Susan , Brockmann, Kathrin , Clark, Lorraine N. , Cookson, Mark , Das, Sayantan , Farrer, Matthew J. , Trinh, Joanne , Gasser, Thomas , Gustavsson, Emil K. , Klein, Christine , Langston, J. William, Lynch, Timothy , Marder, Karen, Martin, Eden R. , Mejia‐Santana, Helen, Molho, Eric , Nuytemans, Karen , Ozelius, Laurie J. , Raymond, Deborah , Ross, Owen A. , Samii, Ali, Saunders‐Pullman, Rachel , Schüle, Birgitt , Tolosa, Eduardo , Tomkins, James E. , Vilas, Dolores , Trojanowski, John Q. , Uitti, Ryan J. , Zabetian, Cyrus P. , Urtreger, Avi Orr, Cannon, P. F. , Fiske, Brian , Brockman, Kathrin , Klein, Christine , Ross, Owen A , Uitti, Ryan, Visanji, Naomi P , Zabetian, Cyrus P , Mirelman, Anat , Alipanahi, Babak , Schwantes-An, Tae-Hwi Linus , Alcalay, Roy N. , Brice, Alexis , Deerlin, Vivianna M. Van , Follett, Jordan , Goldwurm, Stefano , Lang, Anthony E. , Latourelle, Jeanne C. , Marras, Connie , McLean, Cory Y. , Myers, Richard H. , Payami, Haydeh , Rogaeva, Ekaterina A. , Rogers, Michael P. , Schulte, Claudia , Scott, William K. , Tanner, Caroline M. , Vance, Jeffery M. , Visanji, Naomi P. , Wszołek, Zbigniew K. , Giladi, Nir , Foroud, Tatiana

Mayo Clinic

Annals of Neurology | May 3, 2021 | Volume: 90 | Issue: 1 | Pages: 76-88

10.1002/ana.26094 | PMID 33938021 Get It

Objective The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age‐at‐onset of Parkinson's disease. Methods We performed the first genomewide association study of penetrance and age‐at‐onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non‐cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age‐at‐onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age‐at‐onset in LRRK2 mutation carriers. Results A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E‐08, beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co‐immunoprecipitation analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant: p value = 1.1E‐07; age‐at‐onset top variant: p value = 9.3E‐07). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age‐at‐onset. Interpretation This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of LRRK2 mutations. ANN NEUROL 2021;90:82–94